Sanjiang Capital Completes First Close of Its Phase II Biomedical Early-Stage Fund

Recently, Sanjiang Capital’s second early-stage biomedical fund completed its regulatory filing and received the initial batch of paid-in capital. The total size of Sanjiang Phase II Fund is RMB 200 million, with a first close of RMB 110 million. The new fund will continue to focus on early-stage investments in the biomedical industry.

Sanjiang Phase I Fund was established in September 2014 in Suzhou, Jiangsu Province. The fund invested in more than ten medical device and pharmaceutical projects, including Puweisen, Bairuiji, Ruishenan, Tianhong Shengjie, Borui Medicine (688166.SH), and Tekeluo. Under the tireless efforts of the investment team led by Mr. Yang Cuihua, Phase I Fund achieved substantial investment returns, with a distributed paid-in capital (DPI) ratio of 300.8%.